Open AccessPulmonary delivery of sirna for the treatment of cystic fibrosis and pulmonary delivery platforms
Author(s) -
Nensi Raytthatha,
Isha Shah,
Jigar Vyas
Publication year - 2021
Publication title -
world journal of current medical and pharmaceutical research
Language(s) - English
Resource type - Journals
ISSN - 2582-0222
DOI - 10.37022/wjcmpr.v3i6.202
Subject(s) - cystic fibrosis , medicine , genetic enhancement , gene delivery , lung , pulmonary fibrosis , intensive care medicine , bioinformatics , gene , biology , genetics
Cystic fibrosis (CF) is one of the most deadly diseases of lungs that involves symptoms such as breathing difficulties, coughing and lung infection. Despite important therapeutic advances, the definitive treatment for CF remains elusive. CF is a good candidate for gene therapy because it is relatively common, lethal and monogenic and it does not have adequate treatment options. In this review article, we have reviewed gene therapy as a potential treatment option for CF. Various platforms and strategies for pulmonary gene delivery have also been discussed in detail.